Galectin Therapeutics Stock Gross Profit

GALT Stock

USD 1.04 0.96 48.00%

Galectin Therapeutics fundamentals help investors to digest information that contributes to Galectin Therapeutics' financial success or failures. It also enables traders to predict the movement of Galectin Stock. The fundamental analysis module provides a way to measure Galectin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galectin Therapeutics stock.

		Last Reported	Projected for Next Year
	Gross Profit	-33 K	-34.6 K

Gross Profit is likely to drop to about (34.6 K) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Galectin Therapeutics Company Gross Profit Analysis

Galectin Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Current Galectin Therapeutics Gross Profit

(34.7K)

Most of Galectin Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galectin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Galectin Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Galectin Therapeutics is extremely important. It helps to project a fair market value of Galectin Stock properly, considering its historical fundamentals such as Gross Profit. Since Galectin Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Galectin Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Galectin Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.25	-0.32	-0.5	0.25	0.2	1.0	-0.51	0.68	-0.03	-0.46	0.01	0.33	0.69	0.79	0.78	-0.67
Total Stockholder Equity	0.25		-0.99	0.55	-0.83	-0.89	0.26	-0.11	-0.22	0.31	0.03	0.75	0.94	-0.27	0.06	0.12	0.35
Net Debt	-0.32	-0.99		-0.52	0.8	0.86	-0.33	0.18	0.18	-0.26	-0.03	-0.77	-0.94	0.23	-0.09	-0.15	-0.32
Retained Earnings	-0.5	0.55	-0.52		-0.83	-0.8	-0.49	0.39	-0.89	0.24	0.6	0.58	0.56	-0.89	-0.6	-0.54	0.83
Accounts Payable	0.25	-0.83	0.8	-0.83		0.97	0.24	-0.04	0.56	-0.26	-0.34	-0.86	-0.7	0.61	0.39	0.33	-0.71
Total Liab	0.2	-0.89	0.86	-0.8	0.97		0.19	-0.11	0.52	-0.31	-0.25	-0.83	-0.78	0.57	0.33	0.27	-0.68
Total Current Assets	1.0	0.26	-0.33	-0.49	0.24	0.19		-0.51	0.67	-0.03	-0.45	0.02	0.34	0.68	0.79	0.78	-0.66
Short Term Debt	-0.51	-0.11	0.18	0.39	-0.04	-0.11	-0.51		-0.42	0.55	0.47	-0.1	-0.02	-0.33	-0.34	-0.35	0.25
Common Stock	0.68	-0.22	0.18	-0.89	0.56	0.52	0.67	-0.42		0.01	-0.56	-0.21	-0.28	0.99	0.76	0.71	-0.86
Property Plant Equipment	-0.03	0.31	-0.26	0.24	-0.26	-0.31	-0.03	0.55	0.01		0.32	0.19	0.33	0.04	0.27	0.3	-0.04
Current Deferred Revenue	-0.46	0.03	-0.03	0.6	-0.34	-0.25	-0.45	0.47	-0.56	0.32		0.2	0.11	-0.5	-0.3	-0.28	0.34
Net Receivables	0.01	0.75	-0.77	0.58	-0.86	-0.83	0.02	-0.1	-0.21	0.19	0.2		0.57	-0.26	-0.22	-0.2	0.43
Net Tangible Assets	0.33	0.94	-0.94	0.56	-0.7	-0.78	0.34	-0.02	-0.28	0.33	0.11	0.57		-0.28	0.13	0.2	0.3
Capital Surpluse	0.69	-0.27	0.23	-0.89	0.61	0.57	0.68	-0.33	0.99	0.04	-0.5	-0.26	-0.28		0.76	0.7	-0.88
Net Invested Capital	0.79	0.06	-0.09	-0.6	0.39	0.33	0.79	-0.34	0.76	0.27	-0.3	-0.22	0.13	0.76		0.99	-0.86
Net Working Capital	0.78	0.12	-0.15	-0.54	0.33	0.27	0.78	-0.35	0.71	0.3	-0.28	-0.2	0.2	0.7	0.99		-0.8
Capital Stock	-0.67	0.35	-0.32	0.83	-0.71	-0.68	-0.66	0.25	-0.86	-0.04	0.34	0.43	0.3	-0.88	-0.86	-0.8

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Galectin Therapeutics

Gross Profit Over Time

Galectin Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galectin Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galectin Therapeutics could also be used in its relative valuation, which is a method of valuing Galectin Therapeutics by comparing valuation metrics of similar companies.

Galectin Therapeutics is currently under evaluation in gross profit category among its peers.

Galectin Fundamentals

	Return On Equity	-37.28
	Return On Asset	-1.04
	Current Valuation	206.21 M
	Shares Outstanding	62.76 M
	Shares Owned By Insiders	30.95 %
	Shares Owned By Institutions	15.77 %
	Number Of Shares Shorted	5.86 M
	Price To Earning	(4.21) X
	Price To Book	207.70 X
	EBITDA	(202 K)
	Net Income	(41.07 M)
	Cash And Equivalents	15.83 M
	Cash Per Share	0.27 X
	Total Debt	71.81 M
	Current Ratio	1.79 X
	Book Value Per Share	(1.01) X
	Cash Flow From Operations	(32.97 M)
	Short Ratio	42.37 X
	Earnings Per Share	(0.73) X
	Target Price	11.0
	Number Of Employees	14
	Beta	0.63
	Market Capitalization	125.52 M
	Total Asset	28.2 M
	Retained Earnings	(354.37 M)
	Working Capital	12.03 M
	Current Asset	26.4 M
	Current Liabilities	1.36 M
	Net Asset	28.2 M

About Galectin Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Galectin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galectin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galectin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC